HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine

Abstract : Neisseria meningitidis is responsible for the seasonal burden and recurrent epidemics of meningitis in an area of sub-Saharan Africa known as the meningitis belt. Historically, the majority of the cases in the meningitis belt are caused by serogroup A meningococci. Serogroup C meningococci were responsible for outbreaks in the meningitis belt in the 1980s, while serogroup W (formerly W-135) has emerged as a cause of epidemic meningitis since 2000. Serogroup X meningococci have previously been considered a rare cause of sporadic meningitis, but during 2006–2010, outbreaks of serogroup X meningitis occurred in Niger, Uganda, Kenya,Togo and Burkina Faso, the latter with at least 1300 cases of serogroup X meningitis among the 6732 reported annual cases. While serogroup X has not yet caused an epidemic wave of the scale of serogroup A in 1996–1997 or serogroup W in Burkina Faso during 2002, the existing reports suggest a similar seasonal hyperendemicity and capacity for localised epidemics. Serogroup X incidence appears to follow a pattern of highly localised clonal waves, and in affected districts, other meningococcal serogroups are usually absent from disease. Currently, no licensed vaccine is available against serogroup X meningococci. Following the introduction of a monovalent serogroup A conjugate vaccine (MenAfriVac®) in the meningitis belt and the upcoming introduction of pneumococcal conjugate vaccines, vaccine-based prevention of serogroup X may become a public health need. The serogroup X polysaccharide capsule is the most likely target for vaccine development, but recent data also indicate a potential role for protein-based vaccines. A multivalent vaccine, preferably formulated as a conjugate vaccine and covering at least serogroups A, W, and X is needed, and the efforts for vaccine development should be intensified.
Document type :
Journal articles
Complete list of metadata

https://hal.ehesp.fr/hal-03034215
Contributor : Scd Ehesp Connect in order to contact the contributor
Submitted on : Tuesday, December 1, 2020 - 4:31:37 PM
Last modification on : Thursday, April 7, 2022 - 10:10:44 AM

Identifiers

Collections

Citation

Ouli Xie, Andrew Pollard, Judith E. Mueller, Gunnstein Norheim. Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine. Vaccine, Elsevier, 2013, 31 (27), pp.2852-2861. ⟨10.1016/j.vaccine.2013.04.036⟩. ⟨hal-03034215⟩

Share

Metrics

Record views

29